Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. XAIR
XAIR logo

XAIR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Beyond Air Inc (XAIR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.360
1 Day change
-1.91%
52 Week Range
5.840
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Beyond Air Inc (XAIR) is not a good buy for a beginner, long-term investor at this time. The stock exhibits bearish technical indicators, lacks positive trading signals, and has no significant catalysts or financial data to support a strong investment case. Given the investor's impatience and preference for long-term growth, this stock does not align with their goals.

Technical Analysis

The stock is in a bearish trend with moving averages showing SMA_200 > SMA_20 > SMA_5. The MACD histogram is negative (-0.000853) and contracting, while the RSI at 32.582 is neutral but approaching oversold territory. Key support is at 0.343, and resistance is at 0.389. The stock closed at 0.34495, just above the support level, indicating weak price action.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
3

Positive Catalysts

  • NULL identified. No recent news, congress trading data, or significant insider or hedge fund activity.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of trading signals, and no recent news or financial data to support growth. Historical volatility is extremely high (863.98), indicating risk.

Financial Performance

No financial data available for analysis. Latest quarter season data is missing.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available for evaluation.

Wall Street analysts forecast XAIR stock price to rise
2 Analyst Rating
Wall Street analysts forecast XAIR stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.367
sliders
Low
6
Averages
6
High
6
Current: 0.367
sliders
Low
6
Averages
6
High
6
JonesResearch
Buy
maintain
$6 -> $2
AI Analysis
2026-02-19
Reason
JonesResearch
Price Target
$6 -> $2
AI Analysis
2026-02-19
maintain
Buy
Reason
JonesResearch lowered the firm's price target on Beyond Air to $2 from $6 and keeps a Buy rating on the shares following the fiscal Q3 report. The potential commercialization of Beyond Air's second generation LungFit PH system "represents the key inflection point for driving sustainably high revenue growth and profitability," the analyst tells investors in a research note. The firm reduced its sales estimates with the FDA's approval decision not expected until the end of 2026.
Rodman & Renshaw
NULL -> Buy
initiated
$5
2026-01-20
Reason
Rodman & Renshaw
Price Target
$5
2026-01-20
initiated
NULL -> Buy
Reason
Rodman & Renshaw initiated coverage of Beyond Air with a Buy rating and $5 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for XAIR
Unlock Now

People Also Watch